The Ideal LiST Session Frequency Protocol for CPPS Treatment

Chronic Pelvic Pain Syndrome Clinical Trial

Official title:

Comparing 2 Frequency Protocols of Low-intensity Shockwave Therapy for Non-bacterial Chronic Prostatitis Type IIIb /Chronic Pelvic Pain Syndrome: a Randomised Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04549389
• Other study ID #: 1410/2020
• Status: Completed
• Phase: N/A
• Start date: March 2, 2020
• Est. completion date: January 15, 2021

Study information

• Verified date: January 2021
• Source: Institute for the Study of Urological Diseases, Greece
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will include 50 chronic pelvic pain syndrome (CPPS) patients who will be randomised in 2 groups.

Group A (25 patients )will receive 6 LiST sessions with a frequency 1 session / week.

Group B (25 patients) will receive 6 LiST sessions with a frequency 2 sessions / week.

National Institutes of Health Chronic Prostatitis Symptom Index(NHI-CPSI), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-ED) questionnaires will be answered before and at 1 and 3 month follow up visit.

Adverse events will be reported during the treatment and follow up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: January 15, 2021
• Est. primary completion date: October 16, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Participant must 18 to 60 years of age.

2. Participant has signed and dated the appropriate Informed Consent document.

3. Participant has had a clinical diagnosis of CP/CPPS defined as symptoms of discomfort or pain in the perineal or pelvic region for at least a three (3) month period within the last six (6) months

Exclusion Criteria:

1. Participant has evidence of facultative Gram negative or enterococcus with a value of = 1000 CFU/ml in mid-stream urine (VB2).

2. Participant has a history of prostate, bladder or urethral cancer.

3. Participant has undergone pelvic radiation or systemic chemotherapy.

4. Participant has undergone intravesical chemotherapy.

5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition associated with LUTS, any neurological disease or disorder affecting the bladder.

6. Participant has undergone prostate surgery or treatment.

7. Participant with penile or urinary sphincter implants.

8. Participant has been diagnosed with cancer during the last 5 years, or had any surgery in the pelvis.

9. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.

10. PSA>3 and age > 40 years

11. Positive (suspicious for malignancy) digital rectal examination (DRE).

Related Conditions & MeSH terms

• Chronic Non-bacterial Prostatitis Type IIIB
• Chronic Pelvic Pain Syndrome
• Pelvic Pain
• Prostatitis
• Syndrome

Intervention

Device:
• Low intensity shockwave therapy
LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)

Locations

Country	Name	City	State
Greece	G.Gennimatas Hospital	Thessaloniki

Sponsors (1)

Lead Sponsor	Collaborator
Institute for the Study of Urological Diseases, Greece

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1.The difference between groups in the change of the pain domain of NIH-CPSI score	CP/CPPS-related complaints will be assessed by the the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). The questionnaire designed to provide symptom scores for patients with chronic prostatitis. The index provides scores on pain (items 1-4), urinary symptoms (items 5-6), and quality of life (items 7-9).Total score ranges from 0 to 35 (higher values represent worse outcome).The index provides a special pain domain (items 1-4) and the score for this domain ranges from 0 to 21.	from baseline to 12 weeks after final treatment
Secondary	The difference between groups in the change of total NIH-CPSI score (Q1-9)	CP/CPPS-related complaints will be assessed by the the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). The questionnaire designed to provide symptom scores for patients with chronic prostatitis. The index provides scores on pain (items 1-4), urinary symptoms (items 5-6), and quality of life (items 7-9).Total score ranges from 0 to 35 (higher values represent worse outcome)	Time Frame: baseline, 4 and 12 weeks after final treatment
Secondary	The difference between groups in the change of urinary symptoms (Q 5-6) and quality of life domains (Q 7-9) of the NIH-CPSI score	CP/CPPS-related complaints will be assessed by the the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). The questionnaire designed to provide symptom scores for patients with chronic prostatitis. The index provides scores on pain (items 1-4), urinary symptoms (items 5-6), and quality of life (items 7-9).Total score ranges from 0 to 35 (higher values represent worse outcome).The index provides a special urinary symptom domain (items 5-6) and the score for this domain ranges from 0 to 10	from baseline to 4 and 12 weeks after final treatment
Secondary	The difference between groups in the change of IIEF-ED score	It will be assessed by International Index of Erectile Function -Erectile Domain (IEF-ED) score. A questionnaire designed to evaluate erectile capabilities. The questionnaire provides a score between 5 and 30.The severity categories are: 1-10 severe ED, 10-16 moderate ED, 17-21 moderate to mild ED, 22-25 mild ED, 26-30 no ED	from baseline to 4 and 12 weeks after final treatment
Secondary	The difference between groups in the change of IPSS	They will be assessed by the International Prostate Symptom Score (IPSS). A questionnaire designed to provide information on lower urinary tract symptoms and their impact on quality of life. Scores range from 0 to 35. The severity categories are: 1-7 mild, 8-19 moderate, 20-35 severe	from baseline to 4 and 12 weeks after final treatment
Secondary	The difference between groups in the the Pain Visual Analogue Scale (VAS)	It will be assessed by the pain VAS, right after each LIST session. Pain VAS is a unidimensional measure of pain intensity . It is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 [100-mm scale]. To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not recommended. The following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75- 100 mm)	at week 3, 4, 5,
Secondary	Adverse events rate in all patients	Potential treatment related adverse events after the first LIST session and during the 3 month follow up period will be reported	18 weeks